219 related articles for article (PubMed ID: 33022750)
21. No benefit after neoadjuvant chemoradiation in stage IV rectal cancer: A propensity score-matched analysis on a real-world population.
Milito P; Sorrentino L; Pietrantonio F; Di Russo A; Citterio D; Mazzaferro V; Cosimelli M
Dig Liver Dis; 2021 Aug; 53(8):1041-1047. PubMed ID: 33487580
[TBL] [Abstract][Full Text] [Related]
22. Impact of adjuvant chemotherapy after neoadjuvant radio- or radiochemotherapy for patients with locally advanced rectal cancer.
Lichthardt S; Zenorini L; Wagner J; Baur J; Kerscher A; Matthes N; Kastner C; Pelz J; Kunzmann V; Germer CT; Wiegering A
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2363-2373. PubMed ID: 28756493
[TBL] [Abstract][Full Text] [Related]
23. Usefulness of Restaging Pelvis Magnetic Resonance Imaging After Neoadjuvant Concurrent Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer.
Fahmawi Y; Smith C; Grimm L; Khullar S; Rider P; Hunter J; Iliff G; Mneimneh W; Roveda K; Wang B; Prodduturvar P; Alkharabsheh O; McCormick B; Mizrahi M; Khushman M
Clin Colorectal Cancer; 2020 Dec; 19(4):e281-e287. PubMed ID: 32694005
[TBL] [Abstract][Full Text] [Related]
24. Mutation in BRAF and SMAD4 associated with resistance to neoadjuvant chemoradiation therapy in locally advanced rectal cancer.
Jiang D; Wang X; Wang Y; Philips D; Meng W; Xiong M; Zhao J; Sun L; He D; Li K
Virchows Arch; 2019 Jul; 475(1):39-47. PubMed ID: 31056731
[TBL] [Abstract][Full Text] [Related]
25. Clinical and genetic factors associated with tumor response to neoadjuvant (chemo)radiotherapy, survival and recurrence risk in rectal cancer.
Hammarström K; Nunes L; Mathot L; Mezheyeuski A; Lundin E; Korsavidou Hult N; Imam I; Osterlund E; Sjöblom T; Glimelius B
Int J Cancer; 2024 Jul; 155(1):40-53. PubMed ID: 38376070
[TBL] [Abstract][Full Text] [Related]
26. Total Neoadjuvant Therapy Versus Standard Neoadjuvant Chemoradiation in Patients with Locally Advanced Rectal Cancer: A Comparison of Short- and Long-term Oncologic Outcomes.
Goffredo P; Khan A; Mott SL; Jensen CC; Madoff RD; Gaertner WB; You YN; Hassan I
Ann Surg; 2022 Dec; 276(6):e819-e824. PubMed ID: 34353995
[TBL] [Abstract][Full Text] [Related]
27. Integrating Downstaging in the Risk Assessment of Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiotherapy: Validation of Valentini's Nomograms and the Neoadjuvant Rectal Score.
Roselló S; Frasson M; García-Granero E; Roda D; Jordá E; Navarro S; Campos S; Esclápez P; García-Botello S; Flor B; Espí A; Masciocchi C; Valentini V; Cervantes A
Clin Colorectal Cancer; 2018 Jun; 17(2):104-112.e2. PubMed ID: 29162332
[TBL] [Abstract][Full Text] [Related]
28. HER2 status in patients with residual rectal cancer after preoperative chemoradiotherapy: the relationship with molecular results and clinicopathologic features.
Park JS; Yoon G; Kim HJ; Park SY; Choi GS; Kang MK; Kim JG; Jang JS; Seo AN
Virchows Arch; 2018 Oct; 473(4):413-423. PubMed ID: 30056472
[TBL] [Abstract][Full Text] [Related]
29. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis.
Peng J; Lv J; Peng J
Int J Colorectal Dis; 2021 Aug; 36(8):1781-1790. PubMed ID: 33760952
[TBL] [Abstract][Full Text] [Related]
30. Improved survival with adjuvant chemotherapy in locally advanced rectal cancer patients treated with preoperative chemoradiation regardless of pathologic response.
Gahagan JV; Whealon MD; Phelan MJ; Mills S; Jafari MD; Carmichael JC; Stamos MJ; Zell JA; Pigazzi A
Surg Oncol; 2020 Mar; 32():35-40. PubMed ID: 31726418
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of fibroblast growth factor receptor 2 expression in patients with residual rectal cancer after preoperative chemoradiotherapy: relationship with KRAS or BRAF mutations and MSI status.
Yoon G; Lee H; Kim JH; Hur K; Seo AN
Tumour Biol; 2016 Aug; 37(8):10209-18. PubMed ID: 26831663
[TBL] [Abstract][Full Text] [Related]
32. Changes in body composition during neoadjuvant therapy can affect prognosis in rectal cancer patients: An exploratory study.
De Nardi P; Salandini M; Chiari D; Pecorelli N; Cristel G; Damascelli A; Ronzoni M; Massimino L; De Cobelli F; Braga M
Curr Probl Cancer; 2020 Apr; 44(2):100510. PubMed ID: 31703987
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment Tumor Thickness as a Predictor of Pathologic Complete Response to Neoadjuvant Chemoradiation Therapy for Stage II/III Rectal Adenocarcinoma.
Xu B; Chen Y; Guo Y; Zhou D; Yue Z; Duan Q; Yang Y; Guan G; Chi P; Lin C
Am J Clin Oncol; 2018 Jun; 41(6):601-606. PubMed ID: 27672742
[TBL] [Abstract][Full Text] [Related]
34. Thymidine phosphorylase and hypoxia-inducible factor 1-α expression in clinical stage II/III rectal cancer: association with response to neoadjuvant chemoradiation therapy and prognosis.
Lin S; Lai H; Qin Y; Chen J; Lin Y
Int J Clin Exp Pathol; 2015; 8(9):10680-8. PubMed ID: 26617778
[TBL] [Abstract][Full Text] [Related]
35. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics.
Krajnović M; Marković B; Knežević-Ušaj S; Nikolić I; Stanojević M; Nikolić V; Šiljić M; Jovanović Ćupić S; Dimitrijević B
Pathol Res Pract; 2016 Jul; 212(7):598-603. PubMed ID: 27184911
[TBL] [Abstract][Full Text] [Related]
36. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
[TBL] [Abstract][Full Text] [Related]
37. [Comparison of short-term efficacy and perioperative safety between neoadjuvant therapy and total neoadjuvant therapy in patients with locally advanced rectal cancer].
Zhai ZW; Zhang KN; Wang C; Han JG; Ma HC; Wei GH; Yang Y; Wang ZJ
Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):274-280. PubMed ID: 32192307
[No Abstract] [Full Text] [Related]
38. Predictive Factors for Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer.
Zhang Q; Liang J; Chen J; Mei S; Wang Z
Asian Pac J Cancer Prev; 2021 May; 22(5):1607-1611. PubMed ID: 34048192
[TBL] [Abstract][Full Text] [Related]
39. Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation.
Dudani S; Marginean H; Tang PA; Monzon JG; Raissouni S; Asmis TR; Goodwin RA; Gotfrit J; Cheung WY; Vickers MM
BMC Cancer; 2019 Jul; 19(1):664. PubMed ID: 31277604
[TBL] [Abstract][Full Text] [Related]
40. ARID3A Positivity Correlated With Favorable Prognosis in Patients With Residual Rectal Cancer After Neoadjuvant Chemoradiotherapy.
Yoon G; Park JY; Kim HJ; Choi GS; Kim JG; Kang BW; Kang MK; Seo AN
Anticancer Res; 2019 Jun; 39(6):2845-2853. PubMed ID: 31177122
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
